Rush J S, Panneerselvam K, Waechter C J, Freeze H H
Department of Biochemistry, A.B.Chandler Medical Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Glycobiology. 2000 Aug;10(8):829-35. doi: 10.1093/glycob/10.8.829.
Congenital Disorders of Glycosylation (CDG) are human deficiencies in glycoprotein biosynthesis. Previous studies showed that 1 mM mannose corrects defective protein N-glycosylation in cultured fibroblasts from some CDG patients. We hypothesized that these CDG cells have limited GDP-mannose (GDP-Man) and that exogenous mannose increases the GDP-Man levels. Using a well established method to measure GDP-Man, we found that normal fibroblasts had an average of 23.5 pmol GDP-Man/10(6) cells, whereas phosphomannomutase (PMM)-deficient fibroblasts had only 2.3-2.7 pmol/10(6) cells. Adding 1 mM mannose to the culture medium increased the GDP-Man level in PMM-deficient cells to approximately 15.5 pmol/10(6) cells, but had no significant effect on GDP-Man levels in normal fibroblasts. Similarly, mannose supplementation increased GDP-Man from 4.6 pmol/10(6) cells to 24.6 pmol/10(6) cells in phosphomannose isomerase (PMI)-deficient fibroblasts. Based on the specific activity of the GDP-[(3)H]Man pool present in [2-(3)H]mannose labeled cells, mannose supplementation also partially corrected the impaired synthesis of mannosylphosphoryldolichol (Man-P-Dol) and Glc(0)(-)(3)Man(9)GlcNAc(2)-P-P-Dol. These results confirm directly that deficiencies in PMM and PMI result in lowered cellular GDP-Man levels that are corrected by the addition of mannose. In contrast to these results, GDP-Man levels in fibroblasts from a CDG-Ie patient, who is deficient in Man-P-Dol synthase, were normal and unaffected by mannose supplementation even though mannose addition was found to correct abnormal lipid intermediate synthesis in another study (Kim et al. [2000] J. Clin. Invest., 105, 191-198). The mechanism by which mannose supplementation corrects abnormal protein N-glycosylation in Man-P-Dol synthase deficient cells is unknown, but this observation suggests that the regulation of Man-P-Dol synthesis and utilization may be more complex than is currently understood.
先天性糖基化障碍(CDG)是人类糖蛋白生物合成缺陷。先前的研究表明,1 mM甘露糖可纠正某些CDG患者培养的成纤维细胞中缺陷性的蛋白质N-糖基化。我们推测这些CDG细胞的GDP-甘露糖(GDP-Man)有限,并且外源性甘露糖会增加GDP-Man水平。使用一种成熟的方法测量GDP-Man,我们发现正常成纤维细胞平均有23.5 pmol GDP-Man/10⁶个细胞,而磷酸甘露糖变位酶(PMM)缺陷的成纤维细胞仅有2.3 - 2.7 pmol/10⁶个细胞。向培养基中添加1 mM甘露糖可使PMM缺陷细胞中的GDP-Man水平增加至约15.5 pmol/10⁶个细胞,但对正常成纤维细胞中的GDP-Man水平无显著影响。同样,在磷酸甘露糖异构酶(PMI)缺陷的成纤维细胞中,补充甘露糖可使GDP-Man从4.6 pmol/10⁶个细胞增加至24.6 pmol/10⁶个细胞。基于[2-(³H)]甘露糖标记细胞中存在的GDP-[(³H)]Man池的比活性,补充甘露糖还部分纠正了甘露糖基磷酸多萜醇(Man-P-Dol)和Glc₀⁻³Man₉GlcNAc₂-P-P-Dol合成受损的情况。这些结果直接证实,PMM和PMI的缺陷导致细胞内GDP-Man水平降低,而添加甘露糖可纠正这一情况。与这些结果相反,来自一名Man-P-Dol合酶缺陷的CDG-Ie患者的成纤维细胞中的GDP-Man水平正常,且不受甘露糖补充的影响,尽管在另一项研究中发现添加甘露糖可纠正异常的脂质中间产物合成(Kim等人,[2000]《临床研究杂志》,105,191 - 198)。补充甘露糖纠正Man-P-Dol合酶缺陷细胞中异常蛋白质N-糖基化的机制尚不清楚,但这一观察结果表明,Man-P-Dol合成和利用的调节可能比目前所理解的更为复杂。